NCT01391546View on ClinicalTrials.gov

Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)

PHASE3CompletedINTERVENTIONAL

Enrollment

354

Participants

Timeline

Start Date

June 20, 2011

Primary Completion Date

October 15, 2012

Study Completion Date

October 15, 2012

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

ZOSTAVAX

1 dose 0.65 mL

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01391546 - Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045) | Biotech Hunter | Biotech Hunter